Regenxbio Inc (RGNX)

Nov 26, 2024

REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com

Nov 26, 2024

Nov 25, 2024

How To Trade (RGNX) - Stock Traders Daily

Nov 25, 2024

Nov 23, 2024

Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN

Nov 23, 2024

Nov 21, 2024

HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat

Nov 21, 2024

Nov 21, 2024

Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News

Nov 21, 2024

Nov 21, 2024

Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat

Nov 21, 2024

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria

Nov 21, 2024

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 20, 2024

Nov 20, 2024

Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN

Nov 20, 2024

Nov 20, 2024

Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN

Nov 20, 2024

Nov 19, 2024

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology

Nov 19, 2024

Nov 19, 2024

US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Nov 19, 2024

Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Nov 19, 2024

Raymond James maintains $18 target on RGNX after trial data - Investing.com

Nov 19, 2024

Nov 18, 2024

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline

Nov 18, 2024

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive

Nov 18, 2024

Nov 18, 2024

Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat

Nov 18, 2024

Nov 18, 2024

What's Going On With REGENXBIO Shares Monday? - Benzinga

Nov 18, 2024

Nov 18, 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch

Nov 18, 2024

Nov 18, 2024

Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com

Nov 18, 2024

Nov 18, 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire

Nov 18, 2024

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Nov 17, 2024

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 17, 2024

Nov 17, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World

Nov 17, 2024

Nov 15, 2024

Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa

Nov 15, 2024

Nov 15, 2024

Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat

Nov 15, 2024

Nov 15, 2024

5 Analysts Have This To Say About Regenxbio - Benzinga

Nov 15, 2024

Nov 15, 2024

Morgan Stanley Reiterates "Overweight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 15, 2024

Nov 14, 2024

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - Kilgore News Herald

Nov 14, 2024

Nov 14, 2024

REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World

Nov 11, 2024

Nov 11, 2024

HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 11, 2024

REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World

Nov 11, 2024

Nov 11, 2024

Analysts Offer Predictions for REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 11, 2024

HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World

Nov 11, 2024

Nov 10, 2024

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 08, 2024

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Regenxbio: Q3 Earnings Snapshot - The Washington Post

Nov 07, 2024

Nov 06, 2024

RegenXBio Reports Progress Amid Revenue Decline - TipRanks

Nov 06, 2024

Nov 06, 2024

Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia

Nov 06, 2024